Beckman Coulter brings a multicentre spectral AML MRD harmonisation initiative to ICCS 2026
Summary
Beckman Coulter has scheduled a 4 October ICCS 2026 workshop on an international initiative evaluating spectral flow cytometry for AML MRD research, focused on workflow harmonisation, standardized acquisition and analysis, and multicentre implementation. The session had not yet occurred when CFCM checked the source.
Source Date
October 4, 2026
Source checked
October 5, 2026
Event Type
Scheduled workshop / multicentre spectral AML MRD harmonisation initiative
Event Date
October 4, 2026
Geography
International collaboration; ICCS 2026, Miami, USA
Commercial Regulatory Status
Research/clinical-research initiative; no new product authorization or diagnostic approval established by the event page.
Related CFCM Topics
MRD; AML; Spectral Cytometry; Validation / Verification; Multicentre Harmonisation; Evidence; Technology Radar
Category
Technology
Primary source
Read the source →Facts supported by cited sources
Beckman Coulter lists a 4 October ICCS workshop titled Broadening the Spectrum: An International Collaboration in MRD Detection, with Wolfgang Kern and Alan Dunlop. The company says the initiative involves experts from Europe, North America and South America and focuses on harmonizing workflows, standardizing acquisition and analysis, and establishing multicentre best practices.
CFCM explainer
Common workflow → standardized acquisition → common analysis → multicentre reproducibility.
Source/credit: CFCM conceptual explainer based on the primary ICCS workshop description. Alt text: standardisation chain from workflow to multicentre reproducibility.
Claims Requiring Caution
The workshop was still scheduled for later on 4 October when checked. The public page does not provide sample size, participating-site list, panel specification, acceptance criteria or performance results. CFCM therefore records the initiative as announced, not as successful harmonisation.
Why It Matters
Multicentre spectral AML MRD harmonisation addresses a central transferability problem: high dimensionality is only clinically useful if staining, acquisition, unmixing and interpretation can be reproduced across sites. CFCM publishes the initiative as WATCH, not as proof that harmonisation has already succeeded. The next evidence threshold is quantitative inter-site performance.
An announcement is not proof of availability or authorisation. Interpret status within the stated jurisdiction and evidence boundary.
Editor and independence disclosure →